Cargando…

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV

Global use of dexamethasone in COVID-19 patients has revealed a poor understanding of the drug–drug interaction (DDI) potential of dexamethasone, particularly with antiretroviral agents (ARVs). Dexamethasone is both a substrate and a dose-dependent inducer of cytochrome P450 3A4 (CYP3A4). As many AR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Tom G, Marzolini, Catia, Back, David J, Burger, David M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690014/ https://www.ncbi.nlm.nih.gov/pubmed/34791318 http://dx.doi.org/10.1093/jac/dkab412

Ejemplares similares

Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV
por: Zino, Leena, et al.
Publicado: (2022)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

The challenge of HIV treatment in an era of polypharmacy
por: Back, David, et al.
Publicado: (2020)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Magnitude of Drug–Drug Interactions in Special Populations
por: Bettonte, Sara, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Prevalence and management of drug–drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study
por: Schlaeppi, C, et al.
Publicado: (2019)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV
por: Waalewijn, Hylke, et al.
Publicado: (2019)

A Cocktail Interaction Study Evaluating the Drug‐Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
por: Treijtel, Nicoline, et al.
Publicado: (2019)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
por: Stader, Felix, et al.
Publicado: (2018)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
por: Marra, Fiona, et al.
Publicado: (2020)

New drug interactions in HIV and HCV
por: Back, David
Publicado: (2012)

925. Adverse Events Due to Inappropriate Prescribing in Older Adults Living with HIV
por: Cinquegrani, Mark, et al.
Publicado: (2020)

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
por: Bleasby, Kelly, et al.
Publicado: (2021)

Mortality from suicide among people living with HIV and the general Swiss population: 1988‐2017
por: Ruffieux, Yann, et al.
Publicado: (2019)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Violence against women in sex work and HIV risk implications differ qualitatively by perpetrator
por: Decker, Michele R, et al.
Publicado: (2013)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study
por: Schwenke, Johannes M, et al.
Publicado: (2023)

A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
por: Wicha, Sebastian G., et al.
Publicado: (2017)

In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions
por: Martin, Parthena, et al.
Publicado: (2022)

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs
por: Mikus, Gerd, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

The epidemiology of homicide perpetration by children
por: Hemenway, David, et al.
Publicado: (2017)

Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain
por: Castro-Granell, Vanessa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_llg3frgaral4j1fe7a22qpeim6